✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Kayexalate is a drug marketed by Concordia and is included in one NDA.
The generic ingredient in KAYEXALATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
A generic version of KAYEXALATE was approved as sodium polystyrene sulfonate by CMP PHARMA INC on January 19th, 1989.
Recent Clinical Trials for KAYEXALATE
Identify potential brand extensions & 505(b)(2) entrants
|University of California, Irvine||Phase 4|
|Nephrology Research Axis of Maisonneuve Rosemont Hospital||Phase 4|
|Maisonneuve-Rosemont Hospital||Phase 4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Concordia||KAYEXALATE||sodium polystyrene sulfonate||POWDER;ORAL, RECTAL||011287-001||Approved Prior to Jan 1, 1982||DISCN||Yes||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|